nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

18.05.2022 | Editorial

To give or not to give? A critical appraisal of a clinical trial on radioiodine treatment

verfasst von: Murat Tuncel, Alexis Vrachimis, Alfredo Campenni, Bart de Keizer, Frederik A. Verburg, Michael C. Kreissl, Petra Petranovic Ovcaricek, Tamara Geliashvili, Luca Giovanella

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 10/2022

Einloggen, um Zugang zu erhalten

Excerpt

Recently , Leboulleux et al. published the results of the ESTIMABL 2 trial [1]. It is an open-label, randomised, phase III trial using a noninferiority comparison design. In this study, included patients were at the lowest-risk end of the low-risk spectrum of differentiated thyroid cancer (DTC) treated with total thyroidectomy with or without lymph node dissection. Patients were randomised to receive low-dose postoperative radioiodine therapy (RAI) with 1.1 GBq in one group and follow-up without RAI in the second group. We congratulate the authors for this work, representing one of the few randomised trials available in the field. However, we would point out some potential limitations that need to be considered before translating these results to generalised clinical recommendations. …

Leboulleux S, Bournaud C, Chougnet CN, Zerdoud S, Al Ghuzlan A, Catargi B, et al. Thyroidectomy without radioiodine in patients with low-risk thyroid cancer. N Engl J Med. 2022;386:923–32. https://doi.org/10.1056/NEJMoa2111953.CrossRefPubMed

Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26:1–133. https://doi.org/10.1089/thy.2015.0020.CrossRefPubMedPubMedCentral

Ha EJ, Baek JH, Lee JH. Ultrasonography-based thyroidal and perithyroidal anatomy and its clinical significance. Korean J Radiol. 2015;16:749–66. https://doi.org/10.3348/kjr.2015.16.4.749.CrossRefPubMedPubMedCentral

Gulec S, Kuker R. Radioactive iodine remnant ablation: the beta-knife completion thyroidectomy. Mol Imaging Radionucl Ther. 2017;26:16–23. https://doi.org/10.4274/2017.26.suppl.03.CrossRefPubMedPubMedCentral

Bulzacka I, Makarewicz J. Postablative 131I SPECT/CT is much more sensitive than cervical ultrasonography for the detection of thyroid remnants in patients after total thyroidectomy for differentiated thyroid cancer. Clin Nucl Med. 2020;45:948–53. https://doi.org/10.1097/RLU.0000000000003295.CrossRefPubMed

Zilioli V, Peli A, Panarotto MB, Magri G, Alkraisheh A, Wiefels C, et al. Differentiated thyroid carcinoma: incremental diagnostic value of (131)I SPECT/CT over planar whole body scan after radioiodine therapy. Endocrine. 2017;56:551–9. https://doi.org/10.1007/s12020-016-1086-3.CrossRefPubMed

Filetti S, Durante C, Hartl D, Leboulleux S, Locati LD, Newbold K, et al. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-updagger. Ann Oncol. 2019;30:1856–83. https://doi.org/10.1093/annonc/mdz400.CrossRefPubMed

Schmidt M, Bartenstein P, Bucerius J, Dietlein M, Drzezga A, Herrmann K, et al. Individualized treatment of differentiated thyroid cancer: the value of surgery in combination with radioiodine imaging and therapy - a German position paper from Surgery and Nuclear Medicine. Nuklearmedizin. 2022. https://doi.org/10.1055/a-1783-8154.CrossRefPubMed

Verburg FA, Flux G, Giovanella L, van Nostrand D, Muylle K, Luster M. Differentiated thyroid cancer patients potentially benefitting from postoperative I-131 therapy: a review of the literature of the past decade. Eur J Nucl Med Mol Imaging. 2020;47:78–83. https://doi.org/10.1007/s00259-019-04479-1.CrossRefPubMed

10.

Verburg FA, Aktolun C, Chiti A, Frangos S, Giovanella L, Hoffmann M, et al. Why the European Association of Nuclear Medicine has declined to endorse the 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2016;43:1001–5. https://doi.org/10.1007/s00259-016-3327-3.CrossRefPubMed

11.

Chantadisai M, Kingpetch K. Usefulness of (99m)Tc-pertechnetate whole body scan with neck and chest SPECT/CT for detection of post-surgical thyroid remnant and metastasis in differentiated thyroid cancer patients. Ann Nucl Med. 2014;28:674–82. https://doi.org/10.1007/s12149-014-0864-3.CrossRefPubMed

12.

Wang Y, Duan Y, Zhou M, Liu J, Lai Q, Ye B, et al. The diagnostic value of thyroglobulin in fine-needle aspiration of metastatic lymph nodes in patients with papillary thyroid cancer and its influential factors. Surg Oncol. 2021;39: 101666. https://doi.org/10.1016/j.suronc.2021.101666.CrossRefPubMed

13.

Jo K, Kim MH, Lim Y, Jung SL, Bae JS, Jung CK, et al. Lowered cutoff of lymph node fine-needle aspiration thyroglobulin in thyroid cancer patients with serum anti-thyroglobulin antibody. Eur J Endocrinol. 2015;173:489–97. https://doi.org/10.1530/EJE-15-0344.CrossRefPubMed

14.

Grani G, Fumarola A. Thyroglobulin in lymph node fine-needle aspiration washout: a systematic review and meta-analysis of diagnostic accuracy. J Clin Endocrinol Metab. 2014;99:1970–82. https://doi.org/10.1210/jc.2014-1098.CrossRefPubMed

15.

Leenhardt L, Erdogan MF, Hegedus L, Mandel SJ, Paschke R, Rago T, et al. 2013 European thyroid association guidelines for cervical ultrasound scan and ultrasound-guided techniques in the postoperative management of patients with thyroid cancer. Eur Thyroid J. 2013;2:147–59. https://doi.org/10.1159/000354537.CrossRefPubMedPubMedCentral

16.

McCoy CE. Understanding the use of composite endpoints in clinical trials. West J Emerg Med. 2018;19:631–4. https://doi.org/10.5811/westjem.2018.4.38383.CrossRefPubMedPubMedCentral

17.

Palileo-Villanueva LM, Dans AL. Composite endpoints. J Clin Epidemiol. 2020;128:157–8. https://doi.org/10.1016/j.jclinepi.2020.07.017.CrossRefPubMed

18.

Verburg FA, Mader U, Reiners C, Hanscheid H. Long-term survival in differentiated thyroid cancer is worse after low-activity initial post-surgical 131I therapy in both high- and low-risk patients. J Clin Endocrinol Metab. 2014;99:4487–96. https://doi.org/10.1210/jc.2014-1631.CrossRefPubMed

Titel: To give or not to give? A critical appraisal of a clinical trial on radioiodine treatment
verfasst von: Murat Tuncel
Alexis Vrachimis
Alfredo Campenni
Bart de Keizer
Frederik A. Verburg
Michael C. Kreissl
Petra Petranovic Ovcaricek
Tamara Geliashvili
Luca Giovanella
Publikationsdatum: 18.05.2022
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 10/2022
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-022-05841-6

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2022

Construction and implementation of regional high-level PET alliance based on international consensus

The genetic duet of BRAF V600E and TERT promoter mutations predicts the poor curative effect of radioiodine therapy in papillary thyroid cancer

EANM-EAU consensus on PSMA PET/CT in respect to radioligand therapy ([177Lu]Lu-PSMA)

Things are because we see them (O. Wilde): new radiopharmaceuticals for nuclear medicine imaging

[68 Ga]Ga-FAPI uptake correlates with the state of chronic kidney disease

Correction to: An [18F]FDG‑PET/CT deep learning method for fully automated detection of pathological mediastinal lymph nodes in lung cancer patients